(Q37958033)

25 August 2017

title

Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs? (English)

1 reference

25 August 2017

Eugenio Aguglia

2

0 references

Michele Fornaro

object named as

Michele Fornaro

series ordinal

1

0 references

Liliana Dell'Osso

series ordinal

3

object named as

Liliana Dell'Osso

1 reference

25 August 2017

Giulio Perugi

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

18

1 reference

25 August 2017

page(s)

2817-2831

1 reference

Risk for recurrence in depression

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The treatment of depressive states with G 22355 (imipramine hydrochloride).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The three faces of the antidepressants: a critical commentary on the clinical-economic context of diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

CNS drug development. Part I: The early period of CNS drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

SSRI Antidepressant Medications: Adverse Effects and Tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Antidepressants, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The well of novel antidepressants: running dry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Current nosology of treatment resistant depression: a controversy resistant to revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Treatment-resistant bipolar depression: towards a new definition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The catecholamine hypothesis of affective disorders: a review of supporting evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Mode of action of antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The onset of effect for escitalopram and its relevance for the clinical management of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Classical neurotransmitters and neuropeptides involved in major depression: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Neurotransmitters, neurosteroids and neurotrophins: new models of the pathophysiology and treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Where is the room for improvement in the drug treatment of depression and anxiety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Initiation and adaptation: a paradigm for understanding psychotropic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Severe depression: is there a best approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Pathobiological targets of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Therapeutic potential of new second generation antipsychotics for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Diagnostic guidelines for bipolar depression: a probabilistic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Antidepressant treatment in bipolar versus unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Bipolar or unipolar? - the question for clinicians and researchers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The high prevalence of "soft" bipolar (II) features in atypical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

What predicts attrition in second step medication treatments for depression?: a STAR*D Report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

HTR2A gene variation is involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

How accurate are patients in reporting their antidepressant treatment history?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Can single genes matter in a polygenic world?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

21 January 2018

Betting on biomarkers

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Discovering endophenotypes for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Neuropeptide Y (NPY) gene: Impact on emotional processing and treatment response in anxious depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Variation in GNB3 predicts response and adverse reactions to antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Bipolar depression: the real challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The long-term natural history of the weekly symptomatic status of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Bipolarity from ancient to modern times: conception, birth and rebirth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Bipolar Disorder: an impossible diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Is treatment-resistant depression a unique subtype of depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Nosologomania: a disorder of psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

The development of the Feighner criteria: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or discontinuity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

A genome-wide association study of bipolar disorder and comorbid migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Triple reuptake inhibitors: the next generation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for [3H]D-AP5 binding sites on brain membranes and anticonvulsant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Role of GABA in anxiety and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

GABA and circadian timekeeping: implications for manic-depression and sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Antidepressant monotherapy in pre-bipolar depression; predictive value and inherent risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Development and validation of an international risk prediction algorithm for episodes of major depression in general practice attendees: the PredictD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Effects of OPC-14523, a combined sigma and 5-HT1a ligand, on pre- and post-synaptic 5-HT1a receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Basic mechanisms of augmentation of antidepressant effects with thyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632366

10.1517/14656566.2011.632366

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference